edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Herantis Pharma has announced an encouraging update from its ongoing Phase Ib trial for lead asset HER-096, which is being developed as a potential disease-modifying treatment for Parkinson’s disease (PD). Analysis of the part 1 of the Phase 1b trial provided new pharmacokinetic data for HER-096, confirming the expected dosing interval of 2 or 3 subcutaneous doses per week. Further, part 2 of the study has commenced, including the first dosing of a participant diagnosed with PD. Top-line data are anticipated in Q325.
Industrials | Comment
TMT | Comment
Industrials | Comment
Industrials | Comment
Get access to the very latest content matched to your personal investment style.